Natco Pharma Limited (NSE: NATCOPHARM) launches Carboplatin Injection, a generic version of Paraplatin®, in the U.S. market, addressing critical shortages.
Natco Pharma Limited (NATCOPHARM) experiences a 6% intraday decline to ₹892.6, signaling a breakdown in trendline status.
Natco Pharma Limited (NSE: NATCO PHARM) receives tentative approval from U.S. FDA for Olaparib tablets, bioequivalent to Lynparza.
Natco Pharma Limited (NSE: NATCOPHARM) announced the completion of acquiring an additional 13.25% stake in Adcock Ingram, boosting its ownership to 49%.
Natco Pharma Limited (NSE: NATCOPHARM) stock rises 5% intraday to ₹983.6, showing a fresh upward trend despite a breakdown status. Follow the latest updates.
Natco Pharma Limited (NSE: NATCO PHARM) announces FDA approval for Eribulin Mesylate Injection, a bioequivalent to Halaven®.